<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04949282</url>
  </required_header>
  <id_info>
    <org_study_id>SEM-LUT-2020-01</org_study_id>
    <nct_id>NCT04949282</nct_id>
  </id_info>
  <brief_title>Spanish Series of Patients Treated With the Radionuclide Lutetium177</brief_title>
  <acronym>SEPTRALU</acronym>
  <official_title>SEPTRALU, Spanish Series of Patients Treated With the Radionuclide Lutetium177</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sociedad Española de Medicina Nuclear e Imagen Molecular</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sociedad Española de Medicina Nuclear e Imagen Molecular</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to pool the clinical experience of Spanish centers treating patients with&#xD;
      177Lu-DOTATATE to evaluate the efficacy, tolerance, and safety of the drug in routine&#xD;
      clinical practice and to learn about the profiles of patients and tumors treated and the&#xD;
      results in each type of patient and tumor.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patient data will be collected from medical records after obtaining consent and&#xD;
      retrospectively.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 10, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2035</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2034</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Defined as the time, in months, from Lutathera® treatment initiation to the date of first objective tumour progression, determined according to Response Evaluation Criteria in Solid Tumours (RECIST) Criteria, Version 1.1, or death due to any cause, whichever comes first.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Defined as the time, in months, from Lutathera® treatment initiation to the date of death due to any cause.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Is determined by imaging technique according to RECIST criteria v1.1 and is defined as the proportion of treated patients who achieve a best overall response of partial response (PR) or complete response (CR) according to RECIST 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characteristics of the population .</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Description of the main characteristics of the population studied, treatments received (before and after lutetium) and evolution.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events (AEs)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Toxicity will be collected according to grades (NCT-CTCAE) and consequences.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prognostic factors</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Correlation of possible prognostic factors with clinical effectiveness outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Areas for improvement care</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Identification of areas for improvement in the management and selection of patients for treatment with lutathera</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related Quality of Life (HRQoL)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Assess the impact of treatment on health-related Quality of Life (HRQoL) by EORTC QLQ-G.I.NET-21 questionnaire.The minimum value ( 1%) and the maximum value (100%), and higher scores mean a better outcome.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Neuroendocrine Tumors</condition>
  <condition>Intestinal Neoplasms</condition>
  <condition>Pancreatic Neoplasms</condition>
  <condition>Stomach Neoplasms</condition>
  <condition>Neuroectodermal Tumors</condition>
  <condition>Neoplasms, Germ Cell and Embryonal</condition>
  <condition>Neoplasms by Histologic Type</condition>
  <condition>Neoplasms</condition>
  <condition>Neoplasms, Nerve Tissue</condition>
  <condition>Gastrointestinal Neoplasms</condition>
  <condition>Digestive System Neoplasms</condition>
  <condition>Neoplasms by Site</condition>
  <condition>Endocrine Gland Neoplasms</condition>
  <condition>Digestive System Diseases</condition>
  <condition>Gastrointestinal Disease</condition>
  <condition>Intestinal Diseases</condition>
  <condition>Pancreatic Disease</condition>
  <condition>Endocrine System Diseases</condition>
  <arm_group>
    <arm_group_label>Lutathera</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lutetium [177Lu] oxodotreotide/dotatate</intervention_name>
    <description>Radiopharmaceutical solution for infusion (7.4 GBq of Lutathera per 30 ml vial)</description>
    <arm_group_label>Lutathera</arm_group_label>
    <other_name>Lutathera</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Lutetium [177Lu] oxodotreotide/dotatate</intervention_name>
    <description>Radiopharmaceutical solution for infusion (7.4 GBq of Lutathera per 30 ml vial)</description>
    <arm_group_label>Lutathera</arm_group_label>
    <other_name>Lutathera</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study plans to enroll patients with unresectable or metastatic, progressive,&#xD;
        somatostatin receptor positive tumors.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent must be obtained prior to any data collection.&#xD;
&#xD;
          -  Patients must be diagnosed with unresectable or metastatic, progressive, somatostatin&#xD;
             receptor positive tumour&#xD;
&#xD;
          -  Aged ≥18 years.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  None&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mercedes Dr Mitjavila Casanovas, MD-PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sociedad Española de Medicina Nuclear e Imagen Molecular (SEMNIM)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mercedes Dr Mitjavila Casanovas, MD-PhD</last_name>
    <phone>911916000</phone>
    <phone_ext>46261</phone_ext>
    <email>mercedes.mitjavila@salud.madrid.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Paula Dr Jiménez Fonseca, MD-PhD</last_name>
    <phone>985106121</phone>
    <phone_ext>36582</phone_ext>
    <email>palucaji@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Santiago</name>
      <address>
        <city>Santiago De Compostela</city>
        <state>A Coruña</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mercedes Dr Mitjavila Casanovas, MD-PhD</last_name>
      <phone>911916000</phone>
      <phone_ext>46261</phone_ext>
      <email>mercedes.mitjavila@salud.madrid.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de las Nieves</name>
      <address>
        <city>Granada</city>
        <state>Andalucia</state>
        <zip>18014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mercedes Dr Mitjavila Casanovas, MD-PhD</last_name>
      <phone>911916000</phone>
      <phone_ext>46261</phone_ext>
      <email>mercedes.mitjavila@salud.madrid.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <zip>33011</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mercedes Dr Mitjavila Casanovas, MD-PhD</last_name>
      <phone>911916000</phone>
      <phone_ext>46261</phone_ext>
      <email>mercedes.mitjavila@salud.madrid.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Bellvitge</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mercedes Dr Mitjavila Casanovas, MD-PhD</last_name>
      <phone>911916000</phone>
      <phone_ext>46261</phone_ext>
      <email>mercedes.mitjavila@salud.madrid.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Unviersitari Son Espases</name>
      <address>
        <city>Palma De Mallorca</city>
        <state>Islas Baleares</state>
        <zip>07120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mercedes Dr Mitjavila Casanovas, MD-PhD</last_name>
      <phone>911916000</phone>
      <phone_ext>46261</phone_ext>
      <email>mercedes.mitjavila@salud.madrid.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Getafe</name>
      <address>
        <city>Getafe</city>
        <state>Madrid</state>
        <zip>28905</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mercedes Dr Mitjavila Casanovas, MD-PhD</last_name>
      <phone>911916000</phone>
      <phone_ext>46261</phone_ext>
      <email>mercedes.mitjavila@salud.madrid.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Univeritario Puerta de Hierro</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mercedes Dr Mitjavila Casanovas, MD-PhD</last_name>
      <phone>911916000</phone>
      <phone_ext>46261</phone_ext>
      <email>mercedes.mitjavila@salud.madrid.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario Virgen de la Arrixaca</name>
      <address>
        <city>El Palmar</city>
        <state>Murcia</state>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mercedes Dr Mitjavila Casanovas, MD-PhD</last_name>
      <phone>911916000</phone>
      <phone_ext>46261</phone_ext>
      <email>mercedes.mitjavila@salud.madrid.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clínica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mercedes Dr Mitjavila Casanovas, MD-PhD</last_name>
      <phone>911916000</phone>
      <phone_ext>46261</phone_ext>
      <email>mercedes.mitjavila@salud.madrid.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mercedes Dr Mitjavila Casanovas, MD-PhD</last_name>
      <phone>911916000</phone>
      <phone_ext>46261</phone_ext>
      <email>mercedes.mitjavila@salud.madrid.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Burgos</name>
      <address>
        <city>Burgos</city>
        <zip>09006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mercedes Dr Mitjavila Casanovas, MD-PhD</last_name>
      <phone>911916000</phone>
      <phone_ext>46261</phone_ext>
      <email>mercedes.mitjavila@salud.madrid.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Ciudad Real</name>
      <address>
        <city>Ciudad Real</city>
        <zip>13005</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mercedes Dr Mitjavila Casanovas, MD-PhD</last_name>
      <phone>911916000</phone>
      <phone_ext>46261</phone_ext>
      <email>mercedes.mitjavila@salud.madrid.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mercedes Dr Mitjavila Casanovas, MD-PhD</last_name>
      <phone>911916000</phone>
      <phone_ext>46261</phone_ext>
      <email>mercedes.mitjavila@salud.madrid.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mercedes Dr Mitjavila Casanovas, MD-PhD</last_name>
      <phone>911916000</phone>
      <phone_ext>46261</phone_ext>
      <email>mercedes.mitjavila@salud.madrid.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mercedes Dr Mitjavila Casanovas, MD-PhD</last_name>
      <phone>911916000</phone>
      <phone_ext>46261</phone_ext>
      <email>mercedes.mitjavila@salud.madrid.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mercedes Dr Mitjavila Casanovas, MD-PhD</last_name>
      <phone>911916000</phone>
      <phone_ext>42621</phone_ext>
      <email>mercedes.mitjavila@salud.madrid.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario HM Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mercedes Dr Mitjavila Casanovas, MD-PhD</last_name>
      <phone>911916000</phone>
      <phone_ext>46261</phone_ext>
      <email>mercedes.mitjavila@salud.madrid.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Doctor Peset</name>
      <address>
        <city>Valencia</city>
        <zip>46017</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mercedes Dr Mitjavila Casanovas, MD-PhD</last_name>
      <phone>911916000</phone>
      <phone_ext>46361</phone_ext>
      <email>mercedes.mitjavila@salud.madrid.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mercedes Dr Mitjavila Casanovas, MD-PhD</last_name>
      <phone>911916000</phone>
      <phone_ext>46261</phone_ext>
      <email>mercedes.mitjavila@salud.madrid.org</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 14, 2021</study_first_submitted>
  <study_first_submitted_qc>July 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2021</study_first_posted>
  <last_update_submitted>July 1, 2021</last_update_submitted>
  <last_update_submitted_qc>July 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GEP-NET</keyword>
  <keyword>Gastro-Entero-Pancreatic Neuroendocrine Tumour</keyword>
  <keyword>Luthatera</keyword>
  <keyword>Somatostatin receptor positive tumour</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neuroendocrine Tumors</mesh_term>
    <mesh_term>Neuroectodermal Tumors</mesh_term>
    <mesh_term>Neuroectodermal Tumors, Primitive</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
    <mesh_term>Digestive System Neoplasms</mesh_term>
    <mesh_term>Neoplasms by Site</mesh_term>
    <mesh_term>Neoplasms by Histologic Type</mesh_term>
    <mesh_term>Intestinal Neoplasms</mesh_term>
    <mesh_term>Endocrine Gland Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Germ Cell and Embryonal</mesh_term>
    <mesh_term>Neoplasms, Nerve Tissue</mesh_term>
    <mesh_term>Gastrointestinal Diseases</mesh_term>
    <mesh_term>Digestive System Diseases</mesh_term>
    <mesh_term>Pancreatic Diseases</mesh_term>
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Endocrine System Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lutetium Lu 177 dotatate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

